December 25, 2025 05:32 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Tarique Rahman returns to Bangladesh after 17 years | Shocking killing inside AMU campus: teacher shot dead during evening walk | Horror on Karnataka highway: sleeper bus bursts into flames after truck crash, 9 killed | PM Modi attends Christmas service at Delhi church, sends message of love and compassion | Delhi erupts over lynching of Hindu man in Bangladesh; protest outside High Commission | Targeted killing sparks global outrage: American lawmakers condemn mob lynching of Hindu man in Bangladesh | Assam on a ‘powder keg’: Himanta Biswa Sarma flags demographic shift, Chicken’s Neck fears | Bangladesh on edge: Student leader shot as pre-poll violence deepens after Hadi killing | Historic deal sealed: India, New Zealand sign landmark Free Trade Agreement in record time | Supreme court snubs urgent plea to stop PMO’s chadar offering at Ajmer Sharif
Sputnik V
Wallpaper Cave

Argentine scientists say one dose of Russia's Sputnik V develops high immune response

| @indiablooms | Apr 14, 2021, at 02:38 pm

Moscow/Sputnik: The Russian COVID-19 vaccine Sputnik V prompts a high immune response even with a single dose, a study by Argentine scientists and cited by the country's government on Tuesday, has shown.

Last month, the Argentine government decided to delay second doses of vaccines in a bid to offset the shortages in drugs against the COVID-19 disease across the world.

"A global analysis of the immune response induced by the Sputnik V vaccine, in which 288 individuals participated, indicates that 94% showed the presence of specific antibodies after receiving a single dose," the government said, citing the study.

Notably, 61 participants were previously infected with COVID-19. According to the study, they had 4.6 times more antibodies after the Russian vaccine shot than the rest of the group.

The study also revealed that 96 percent of people under 60 developed antibodies within 21 days after getting vaccinated. The rate stands at 89 percent among those aged over 60.
After two doses of Sputnik V, 100 percent of immunized people have antibodies, the study also noted.

Sputnik V has so far been approved for use in 60 states across the world. According to phase 3 trial results published in The Lancet medical journal, the vaccine has 91.6 percent efficacy against symptomatic COVID-19.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.